消息

Risk factors remain concentrated: current revenues rely entirely on Kimmtrak, and the company lacks collaboration agreements for its pipeline candidates. Execution risks increase as the firm enters larger, more competitive markets. Potential catalysts for 2026 include second‑half cutaneous melanoma data for Brenetafusp, further Kimmtrak adoption in...

全文

Immunocore is broadening its ImmTAC platform beyond Kimmtrak. The ImmTAX technology is in clinical testing for solid tumors, infectious diseases, and autoimmune conditions. Brenetafusp, a lead candidate, is in phase III for first‑line advanced cutaneous melanoma, while other programs target colorectal and gastrointestinal cancers. Expansion into no...

全文

The company’s balance sheet is strong, ending March 31 2026 with $844.9 million in cash and marketable securities. Earnings rose to 25 cents per share, beating consensus expectations of a 26‑cent loss. Immunocore trades at a price‑to‑sales multiple of 3.4 ×, a premium that hinges on sustained Kimmtrak growth and pipeline progress.

全文

Kimmtrak generated $106.7 million in first‑quarter 2026 revenue, a 14 % year‑over‑year increase, and totaled $400 million in 2025 sales, up 29 % from the previous year. The drug is approved in 39 countries, launched in more than 30, and its 5‑year phase III data showed a 16 % overall‑survival rate versus 8 % for control, reinforcing its first‑line...

全文

Although Eagle’s SMR initiative is still in early stages, the company’s integrated approach—combining domestic uranium resources with proprietary SMR technology—positions it to contribute to the United States’ nuclear fuel needs if domestic production is prioritized. The update underscores the company’s progress toward advancing the Aurora Project...

全文

The company is also advancing a small‑modular‑reactor (SMR) program in partnership with Tensor Medium Corporation, leveraging AI‑enabled reactor modeling and simulation to accelerate design efforts. Eagle’s strategy seeks to capture value across both uranium supply and SMR technology, contrasting with peers such as Cameco and Uranium Energy Corp.,...

全文

Key milestones for the PFS have been achieved: permit applications were filed with the Bureau of Land Management; a meteorological station has been installed; and wetland delineation and cultural surveys have been completed. These activities reduce permitting, environmental baseline, and drill‑program risks ahead of the PFS.

全文

Eagle Nuclear Energy Corp. (NASDAQ: NUCL) announced its second‑quarter 2026 corporate update on the Aurora Uranium Project, which contains 32.75 million pounds of indicated uranium and 4.98 million pounds of inferred uranium—making it one of the largest conventional measured and indicated uranium deposits in the United States. The company is target...

全文

Financially, Forte reported a first‑quarter net loss of $1.24 per share, down from $1.37 per share a year earlier, and the acquisition will provide a significant capital influx. argenx’s global reach, development expertise, and commercial capabilities are expected to unlock FB102’s full potential and maximize its impact for patients.

全文

Forte’s stock surged 39‑40 % in pre‑market trading, with intraday volume rising to more than 14 million shares compared with a daily average of roughly 505 000. The share price moved close to the $77 offer price, reflecting strong investor confidence in deal completion. The announcement followed argenx’s earlier strategic investment in Forte, and t...

全文